Analysts Expect GW Pharmaceuticals PLC (GWPH) to Post -$1.39 EPS
Equities research analysts expect GW Pharmaceuticals PLC (NASDAQ:GWPH) to report earnings per share (EPS) of ($1.39) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for GW Pharmaceuticals PLC’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($2.12). GW Pharmaceuticals PLC reported earnings of ($0.89) per share during the same quarter last year, which would indicate a negative year over year growth rate of 56.2%. The company is scheduled to report its next earnings results on Monday, December 4th.
According to Zacks, analysts expect that GW Pharmaceuticals PLC will report full-year earnings of ($5.99) per share for the current fiscal year, with EPS estimates ranging from ($6.66) to ($5.04). For the next year, analysts anticipate that the firm will post earnings of ($6.43) per share, with EPS estimates ranging from ($6.96) to ($6.13). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for GW Pharmaceuticals PLC.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $2.10 million. During the same period in the prior year, the business earned ($0.05) EPS.
A number of equities research analysts recently commented on the company. Zacks Investment Research cut GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $124.00 target price on shares of GW Pharmaceuticals PLC in a research note on Friday, October 6th. Maxim Group set a $135.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, Cantor Fitzgerald set a $208.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $143.05.
Several institutional investors and hedge funds have recently made changes to their positions in the company. IHT Wealth Management LLC raised its position in GW Pharmaceuticals PLC by 18.0% during the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares during the last quarter. Advisor Group Inc. raised its position in GW Pharmaceuticals PLC by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares during the last quarter. BNP Paribas Arbitrage SA bought a new position in GW Pharmaceuticals PLC during the 2nd quarter worth $163,000. Blair William & Co. IL bought a new position in GW Pharmaceuticals PLC during the 1st quarter worth $207,000. Finally, Ameriprise Financial Inc. bought a new position in GW Pharmaceuticals PLC during the 1st quarter worth $230,000. Institutional investors own 75.06% of the company’s stock.
Shares of GW Pharmaceuticals PLC (GWPH) traded down 0.40% on Tuesday, reaching $110.81. The company had a trading volume of 163,218 shares. The company has a 50-day moving average price of $107.97 and a 200-day moving average price of $107.72. The firm’s market cap is $2.81 billion. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $136.95.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.